| Title: | Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study |
| Journal: | Alzheimer's Research & Therapy |
| Published: | 26 Jun 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38926784/ |
| DOI: | https://doi.org/10.1186/s13195-024-01498-5 |
| URL: | https://alzres.biomedcentral.com/counter/pdf/10.1186/s13195-024-01498-5 |
Publication 11786
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundLiver disease and dementia are both highly prevalent and share common pathological mechanisms. We aimed to investigate the associations between metabolic dysfunction-associated fatty liver disease (MAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk of all-cause and cause-specific dementia.MethodsWe conducted a prospective study with 403,506 participants from the UK Biobank. Outcomes included all-cause dementia, Alzheimer's disease, and vascular dementia. Multivariable Cox proportional hazards models were used for analyses.Results155,068 (38.4%) participants had MAFLD, and 111,938 (27.7%) had MASLD at baseline. During a median follow-up of 13.7 years, 5,732 participants developed dementia (2,355 Alzheimer's disease and 1,274 vascular dementia). MAFLD was associated with an increased risk of vascular dementia (HR 1.32 [95% CI 1.18-1.48]) but a reduced risk of Alzheimer's disease (0.92 [0.84-1.0]). Differing risks emerged among MAFLD subtypes, with the diabetes subtype increasing risk of all-cause dementia (1.8 [1.65-1.96]), vascular dementia (2.95 [2.53-3.45]) and Alzheimer's disease (1.46 [1.26-1.69]), the lean metabolic disorder subtype only increasing vascular dementia risk (2.01 [1.25-3.22]), whereas the overweight/obesity subtype decreasing risk of Alzheimer's disease (0.83 [0.75-0.91]) and all-cause dementia (0.9 [0.84-0.95]). MASLD was associated with an increased risk of vascular dementia (1.24 [1.1-1.39]) but not Alzheimer's disease (1.0 [0.91-1.09]). The effect of MAFLD on vascular dementia was consistent regardless of MASLD presence, whereas associations with Alzheimer's disease were only present in those without MASLD (0.78 [0.67-0.91]).ConclusionsMAFLD and MASLD are associated with an increased risk of vascular dementia, with subtype-specific variations observed in dementia risks. Further research is needed to refine MAFLD and SLD subtyping and explore the underlying mechanisms contributing to dementia risk.</p>
9 Authors
- Xue Bao
- Lina Kang
- Songjiang Yin
- Gunnar Engström
- Lian Wang
- Wei Xu
- Biao Xu
- Xiaowen Zhang
- Xinlin Zhang
1 Application
| Application ID | Title |
|---|---|
| 91907 | Effects of glucose-lowering drugs on cardiac arrhythmia, it's drivers and related outcomes |
Enabling scientific discoveries that improve human health